Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases)
Strategic Profile
Entrada's primary focus is Duchenne muscular dystrophy (DMD), with Phase 1/2 studies of ENTR-601-44 and ENTR-601-45, and planned development of ENTR-601-50 and ENTR-601-51. The company gained FDA Rare Pediatric Disease Designation for ENTR-601-44 and ended 2025 with $295.7M in cash with runway into Q3 2027.
Cyborg Score Rationale
The company expects Phase 1/2 data readouts in Q2 2026 for Cohort 1 and year-end for Cohort 2 of its lead DMD program. Recent positive DMC recommendations to escalate dosing support clinical progress. However, the company is currently unprofitable and not forecast to become profitable over the next 3 years.
Top Insights
Independent DMC recommended dose escalation in ELEVATE-44-201 to 12 mg/kg with Cohort 1 data expected Q2 2026 and Cohort 2 data by year-end.
FDA granted Rare Pediatric Disease Designation to ENTR-601-44 in December 2025, providing potential regulatory advantages.
Guggenheim upgraded TRDA to strong-buy rating on February 11th, 2026.
Company expects four clinical-stage DMD programs in development for 2026, plus VX-670 partnership with Vertex for myotonic dystrophy type 1.
Named Competitors
Intracellular therapeutics — Targeted protein degradation
Ocular/retinal diseases — Anti-VEGF biologics for wet AMD
RNA-based therapeutics — Genetic medicine for myotonic dystrophy
Recent Developments
(February 26, 2026) Q4 2025 and full-year results reported with DMC recommendation for ELEVATE-44-201 Cohort 2 dose escalation to 12 mg/kg and ENTR-801 nomination for USH2A.
(December 2025) FDA granted Rare Pediatric Disease Designation to ENTR-601-44.
(Q1 2026 outlook) Multiple clinical readouts expected including Phase 1/2 MAD study initiation of ENTR-601-50 by end-2026 and global regulatory submissions for ENTR-601-51.
Open the full interactive Entrada Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.